Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
2016; Springer Science+Business Media; Volume: 22; Issue: 6 Linguagem: Inglês
10.1007/s13365-016-0449-0
ISSN1538-2443
AutoresMilton H. Werner, DeRen Huang,
Tópico(s)Antenna Design and Analysis
ResumoSixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive patients were longitudinally sampled for up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of patients were found to excrete virus, consistent with the prevalence of urinary excretion in the general population. Unexpectedly, urinary excretion was predominantly seen (>73 %) in patients with high JC antibody index (≥2.0). Active JCV infection, therefore, tends to occur in natalizumab patients that carry a high risk factor for the development of disease, directly linking JC infection to the risk factors for PML development.
Referência(s)